Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of OK-101 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT05759208 is registered in ClinicalTrials.gov with Okyo Pharma Ltd as lead sponsor.

NCT NCT05759208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of OK-101 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Lead sponsor
Okyo Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2023
Completion date
December 15, 2023
Enrollment
240 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease